Advice

Strontium ranelate discontinued

In August 2017, due to limited demand, attributed to restrictions on its indication and additional monitoring requirements that followed a review by the European Medicines Agency of the risks and benefits of treatment, Les Laboratoires Servier, ceased the distribution of strontium ranelate (Protelos), for the treatment of osteoporosis in men at increased risk of fracture.

Medicine details

Medicine name:
strontium ranelate (Protelos)
SMC ID:
816/12
Indication:
Treatment of osteoporosis in men at increased risk of fracture.
Pharmaceutical company
Servier Laboratories Ltd
BNF chapter
Endocrine system
Submission type
Non submission
Status
Withdrawn
Date advice published:
08 October 2012